Alliances forged at summit to enhance regulation of China’s pharmaceutical industry

More than 300 leaders and experts attended a recent conference at Xi’an Jiaotong-Liverpool University to exchange ideas on issues affecting regulation and compliance within China’s pharmaceutical industry.

Discussions at the China Pharmacy Regulation Summit and Zijin Forum for China Pharmacy Compliance delved into key aspects and procedures spanning the entire drug lifecycle, from research and registration to production and distribution.

Professor Zhoulin Ruan

The event, co-hosted by XJTLU and the China Pharmaceutical University’s National Drug Policy and Ecosystem, attracted regulatory officials, scholars, industry professionals, lawyers, company executives, and compliance officers.

During the event, the XJTLU Wisdom Lake Academy of Pharmacy and the China Pharmaceutical University’s Institute for Drug Regulatory Science (IDRS) unveiled the Full Lifecycle Compliance Capability Enhancement Plan for Biopharmaceutical Enterprises, which looks at possible areas for improvement and cooperation to cultivate high-quality talent in the field.

The Compliance Alliance of Biopharmaceutical Enterprises in SIP

The two institutions also entered into a strategic cooperation agreement to foster the integration of industry, academia, and governance within the realm of regulatory science.

“The partnership between these institutions will help integrate the academic prowess of universities with the industrial strengths in the biopharmaceutical sector possessed by Suzhou and Suzhou Industrial Park (SIP),” said Miao Chen, Deputy Director of the Management Committee of the SIP Lake Science and Education Innovation Zone. “This collaboration is poised to bolster the industry’s high-quality, efficient, and sustainable development.”

In addition, the Academy is gearing up to launch a research-oriented master’s degree programme in pharmaceutical regulatory science in September 2024.

The conference also witnessed the establishment of the Compliance Alliance of Biopharmaceutical Enterprises in SIP, which promises to work with government and academic institutions to enhance enterprise compliance capabilities, encourage initiatives that nurture top talents, conduct research, and seek valuable expert advice to help shape policies.

“While advancing the industry, we recognise the crucial role of orderly development and compliant operation for the industry’s healthy growth,” said Jianguo Yin, Chairman of SIP Bioindustry Development Co.

The event's attendees

The alliance’s inaugural members are BioBAY, XJTLU, the China Pharmaceutical University, GenePharma, Abogen Biosciences, CATUG Biotechnology, PegBio, Porton Pharma Solutions, Lexenpharm (Suzhou), Kintor Pharmaceutical, and Gracell Biotechnologies.

During the summit, Professor Zhoulin Ruan, Vice President of Academic Affairs at XJTLU, stressed XJTLU’s proactive role in reshaping how universities function in society by serving as catalysts. “By hosting this summit, XJTLU has taken a concrete step to strengthen ties among society, industry, and academia in the field of regulatory science,” he said.

Photo and text courtesy of XJTLU Wisdom Lake Academy of Pharmacy
Translated by Xueqi Wang
Edited by Luyun Shi and Patricia Pieterse